Gan & Lee Pharmaceuticals.
603087
Kedudukan dalam Saham
#3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Harga Saham
$10.03
Modal Pasaran
$5.99B
Perubahan (1 hari)
-3.71%
Perubahan (1 tahun)
2.30%
Negara
CN
Perdagangan Gan & Lee Pharmaceuticals. (603087)
Kategori
Healthcare
Sejarah hasil dividen untuk Gan & Lee Pharmaceuticals. (603087)
Hasil dividen (TTM) bagi Gan & Lee Pharmaceuticals. (simbol saham: 603087) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.92%
Purata hasil dividen 5 tahun terakhir: 0.92%
Sejarah hasil dividen untuk Gan & Lee Pharmaceuticals. (603087) dari 2013 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Ubah |
|---|---|---|
| 2025 | 1.48% | -8.07% |
| 2024 | 1.61% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | 0.92% | 61.40% |
| 2021 | 0.57% | 111.11% |
| 2020 | 0.27% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | 0.01% | 0.00% |
| 2016 | 0.01% | 0.00% |
| 2015 | 0.01% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | 0.09% | 0.00% |
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
| Syarikat | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 2.70% |
FR
|
|
| 0.00% |
JP
|
|
| 2.10% |
US
|
|
| 0.00% |
CH
|
